<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59709">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328677</url>
  </required_header>
  <id_info>
    <org_study_id>6407</org_study_id>
    <nct_id>NCT02328677</nct_id>
    <nct_alias>NCT02391597</nct_alias>
  </id_info>
  <brief_title>ColoCare Study - Colorectal Cancer Cohort</brief_title>
  <official_title>ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huntsman Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ColoCare is an international prospective cohort study of stage I-IV colorectal cancer
      patients (ICD-10 C18-C20).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ColoCare Consortium is a multicenter initiative establishing an international cohort of
      colorectal cancer (CRC) patients for interdisciplinary studies of CRC prognosis and outcomes
      with sites at the Fred Hutchinson Cancer Research Center, Seattle (Washington, USA), H. Lee
      Moffitt Cancer Center and Research Institute, Tampa (Florida, USA), the University Hospital
      Heidelberg (Germany) and the Huntsman Cancer Institute (Utah, USA).

      Aims: The ColoCare Study investigates clinical outcomes, including disease-free and overall
      survival, predictors of cancer recurrence, survival, health-related quality-of-life and
      treatment toxicities. In addition, cross-sectional analyses of biomarkers and/or health
      behaviors are undertaken.

      Patients are recruited at baseline (time of first diagnosis) and followed for up to 5 years
      at regular timepoints (3m, 6m, 12m, 24m, 36m, 48m, 60m). The cohort includes a comprehensive
      collection of specimens and data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">October 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free and overall survival</measure>
    <time_frame>up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>at 0, 3, 6, 12, 24, 36, 48, 60 months post recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment toxicities</measure>
    <time_frame>up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ColoCare FHCRC</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status Aug 2016: n= 349</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ColoCare Moffitt (affiliated cohort)</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status Aug 2016: n=464</description>
  </arm_group>
  <arm_group>
    <arm_group_label>University Hospital Heidelberg</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status Aug 2016: n=539</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ColoCare Huntsman Cancer Institute</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status Aug 2016: n=69</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, feces, saliva, FFPE and fresh frozen tissue (multiple sources/locations), DNA,
      RNA, miRNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ColoCare is an international prospective cohort study of stage I-IV colorectal cancer
        patients (ICD-10 C18-C20). The ColoCare Consortium is a multicenter initiative of
        interdisciplinary research on CRC outcome and prognosis, and comprises patient recruitment
        at 4 sites. Patients are recruited at baseline (time of first diagnosis, time prior to
        surgery or during treatment (FHCRC and HCI)) and followed for up to 10 years at regular
        timepoints (3m, 6m, 12m, 24m, 36m, 48m, 60m). The cohort includes a comprehensive
        collection of biospecimens and data.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-89 years;

          2. Men and Women

          3. Newly-diagnosed colon or rectal cancer (stages I-IV); CRC in treatment (FHCRC and
             HCI)

          4. English (FHCRC, Moffitt, HCI) or German (University Hospital Heidelberg)-speaking;

          5. mentally/physically able to consent and participate.

        Exclusion Criteria:

          -  if one of the above in not fulfilled

          -  insufficient language or consent capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia M Ulrich, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Grady, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexis Ulrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erin Siegel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lee H. Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cornelia Ulrich, MS, PhD</last_name>
    <phone>(801) 213-5716</phone>
    <email>neli.ulrich@hci.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William Grady, MD</last_name>
    <phone>(206) 667-1107</phone>
    <email>wgrady@fhcrc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lee H. Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>12902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Siegel, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Ulrich, MS, PhD</last_name>
      <email>neli.ulrich@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FHCRC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Ulrich, MS, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>William Grady, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Cornelia, MS, PhD</last_name>
      <email>neli.ulrich@hci.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 10, 2016</lastchanged_date>
  <firstreceived_date>November 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>rectosigmoid</keyword>
  <keyword>rectum</keyword>
  <keyword>colon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
